Bellevue Group Ag Coherus Bio Sciences, Inc. Transaction History

Bellevue Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$14.42 - $21.39 $2.15 Million - $3.19 Million	-149,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $20.8 Million - $23.8 Million	-1,254,400 Reduced 89.38%	149,000 $2.59 Million
Q3 2020 Nov 16, 2020	BUY	$17.41 - $19.89 $4.28 Million - $4.89 Million	246,000 Added 21.25%	1,403,400 $25.7 Million
Q2 2020 Aug 13, 2020	BUY	$14.43 - $19.16 $16 Million - $21.2 Million	1,108,900 Added 2286.39%	1,157,400 $20.7 Million
Q1 2020 May 14, 2020	SELL	$11.67 - $22.53 $1.17 Million - $2.25 Million	-100,000 Reduced 67.34%	48,500 $787,000
Q4 2019 Feb 14, 2020	SELL	$16.33 - $21.37 $864,428 - $1.13 Million	-52,935 Reduced 26.28%	148,500 $2.67 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $567,240 - $813,276	34,800 Added 20.88%	201,435 $4.08 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $1.97 Million - $3.33 Million	-150,500 Reduced 47.46%	166,635 $3.68 Million
Q1 2019 May 15, 2019	SELL	$8.38 - $15.5 $350,284 - $647,900	-41,800 Reduced 11.65%	317,135 $4.33 Million
Q4 2018 Feb 12, 2019	BUY	$8.65 - $16.28 $1.24 Million - $2.33 Million	143,000 Added 66.22%	358,935 $3.25 Million
Q3 2018 Nov 13, 2018	BUY	$14.45 - $20.25 $261,545 - $366,525	18,100 Added 9.15%	215,935 $3.56 Million
Q2 2018 Aug 07, 2018	BUY	$10.25 - $17.45 $490,308 - $834,720	47,835 Added 31.89%	197,835 $2.77 Million
Q4 2017 Feb 14, 2018	BUY	$8.35 - $14.4 $1.25 Million - $2.16 Million	150,000	150,000 $1.32 Million

143

82.7M

79.1K

100K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $80.8M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.